Cargando…

Association Between Hematologic Response and Change in Health-Related Quality of Life Among Patients with Light-Chain (AL) Amyloidosis

PURPOSE: The purpose of this secondary data analysis was to examine the association between hematologic response and health-related quality of life (HRQoL) among patients with light-chain (AL) amyloidosis. PATIENTS AND METHODS: Data for this secondary analysis were collected through a non-interventi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rizio, Avery A, McCausland, Kristen L, Carty, Michelle K, Conrad, Ansgar, Quock, Tiffany P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576564/ https://www.ncbi.nlm.nih.gov/pubmed/37840834 http://dx.doi.org/10.2147/PROM.S421211

Ejemplares similares

Work Outcomes Among Patients with Light Chain (AL) Amyloidosis: Findings from Three Patient Cohorts
por: Rizio, Avery A, et al.
Publicado: (2021)

Associations between Health-Related Quality of Life and Self-Reported Emergency Room Department Visits and Inpatient Hospitalizations: Insights from a Secondary Data Analysis of Patients with Light-Chain (AL) Amyloidosis
por: McCausland, Kristen L., et al.
Publicado: (2019)

Light Chain (AL) Amyloidosis: The Journey to Diagnosis
por: McCausland, Kristen L., et al.
Publicado: (2017)

The burden of amyloid light chain amyloidosis on health-related quality of life
por: Bayliss, Martha, et al.
Publicado: (2017)

Health-Related Quality of Life Instruments for Clinical Trials in AL Amyloidosis: Report from the Amyloidosis Forum HRQOL Working Group
por: Rizio, Avery A, et al.
Publicado: (2023)

Content validation of the SF-36v2® health survey with AL amyloidosis patients
por: White, Michelle K., et al.
Publicado: (2017)

Content Validation of the ATTR Amyloidosis Patient Symptom Survey: Findings from Patient and Clinician Cognitive Debriefing Interviews
por: Rizio, Avery A, et al.
Publicado: (2020)

Psychometric validation of the SF-36 Health Survey in light chain amyloidosis: results from community-based and clinic-based samples
por: White, Michelle K, et al.
Publicado: (2017)

A longitudinal evaluation of health‐related quality of life in patients with AL amyloidosis: associations with health outcomes over time
por: Sanchorawala, Vaishali, et al.
Publicado: (2017)

The Transthyretin Amyloidosis – Quality of Life (ATTR-QOL) Questionnaire: Development of a Conceptual Model and Disease-Specific Patient-Reported Outcome Measure
por: O’Connor, Meaghan, et al.
Publicado: (2023)

PB2135: TREATMENT PATTERNS IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS
por: D’souza, Anita, et al.
Publicado: (2023)

PB2154: THE IMPACT OF DISEASE SEVERITY ON THE CLINICAL AND ECONOMIC BURDEN OF AL AMYLOIDOSIS
por: D’souza, Anita, et al.
Publicado: (2023)

The Burden of Sickle Cell Disease on Children and Their Caregivers: Caregiver Reports of Children’s Health-Related Quality of Life and School Experiences, Caregiver Burden, and Their Association with Frequency of Vaso-Occlusive Crises
por: Campbell, Andrew, et al.
Publicado: (2023)

In-hospital mortality in amyloid light chain amyloidosis: analysis of the Premier Healthcare Database
por: Quock, Tiffany P, et al.
Publicado: (2022)

The relationship between frequency and severity of vaso-occlusive crises and health-related quality of life and work productivity in adults with sickle cell disease
por: Rizio, Avery A., et al.
Publicado: (2020)

Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis
por: Gertz, Morie, et al.
Publicado: (2023)

Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
por: Palladini, Giovanni, et al.
Publicado: (2021)

Light chain (AL) amyloidosis: update on diagnosis and management
por: Rosenzweig, Michael, et al.
Publicado: (2011)

Early Data on Long-term Impact of Inotersen on Quality-of-Life in Patients with Hereditary Transthyretin Amyloidosis Polyneuropathy: Open-Label Extension of NEURO-TTR
por: Yarlas, Aaron, et al.
Publicado: (2021)

Clinical and prognostic implications of capillary density in patients with cardiac light chain amyloidosis
por: Kim, Darae, et al.
Publicado: (2021)

Extensive Amyloid Purpura: An Unusual Presentation of Myeloma-associated Light Chain Amyloidosis
por: JABER, Nor Fazil, et al.
Publicado: (2023)

Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2018)

Racial disparities in patients diagnosed with light chain (AL) amyloidosis
por: D’Souza, Anita, et al.
Publicado: (2021)

Light Chain (AL) Cardiac Amyloidosis: A Diagnostic Dilemma
por: Abdelazeem, Basel, et al.
Publicado: (2021)

Differences in Immunoglobulin Light Chain Species Found in Urinary Exosomes in Light Chain Amyloidosis (AL)
por: Ramirez-Alvarado, Marina, et al.
Publicado: (2012)

Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis
por: Morgan, Gareth J., et al.
Publicado: (2021)

Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis
por: Wechalekar, A D, et al.
Publicado: (2017)

PB1989: LIGHT CHAIN AMYLOIDOSIS (AL): THE EXPERIENCE OF A TUNISIAN CENTER
por: Kallel, F., et al.
Publicado: (2022)

Supportive Care and Symptom Management for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
por: Jensen, Christopher E., et al.
Publicado: (2022)

Mutations in Specific Structural Regions of Immunoglobulin Light Chains Are Associated with Free Light Chain Levels in Patients with AL Amyloidosis
por: Poshusta, Tanya L., et al.
Publicado: (2009)

Novel Therapies in Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2017)

DUAL expectations in light chain amyloidosis
por: Schönland, Stefan, et al.
Publicado: (2020)

Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States
por: Quock, Tiffany P, et al.
Publicado: (2019)

A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis
por: Sidana, Surbhi, et al.
Publicado: (2020)

Splenic rupture secondary to amyloid light-chain (AL) amyloidosis associated with multiple myeloma
por: Buzalewski, Jarrod, et al.
Publicado: (2019)

Lingual liability: macroglossia and dyspnoea as the harbinger of systemic AL (light-chain) cardiac amyloidosis
por: Williams, Michael Uncle, et al.
Publicado: (2018)

Understanding Mesangial Pathobiology in AL-Amyloidosis and Monoclonal Ig Light Chain Deposition Disease
por: Herrera, Guillermo A., et al.
Publicado: (2020)

Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives
por: Sarosiek, Shayna, et al.
Publicado: (2019)

The Role of Light Kappa and Lambda Chains in Heart Function Assessment in Patients with AL Amyloidosis
por: Czyżewska, Emilia, et al.
Publicado: (2021)

Autopsy findings in a patient with primary systemic AL (kappa light chain) amyloidosis
por: Ledesma, Felipe Lourenço, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4l3q8ul26mvho1dog586vsn12p